|Dr. Michael R. Bristow||Co-Founder, Pres, CEO & Director||296.15k||N/A||1945|
|Mr. Thomas A. Keuer||Chief Operating Officer||304.02k||N/A||1959|
|Mr. Christopher D. Ozeroff||Sr. VP, Gen. Counsel & Sec.||290.16k||N/A||1959|
|Mr. Brian L. Selby||Chief Accounting Officer & VP of Fin.||N/A||N/A||1962|
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.